Medical Cannabis and CBD Rules in Poland: Legal Access in Warsaw and Beyond

Poland’s cannabis landscape differs dramatically from what many North American consumers expect. There are no recreational dispensaries, no corner cannabis shops, and no walk-in purchases without a prescription. If you’re planning to visit Warsaw or relocate to Poland and want to understand your options, you need accurate information about what’s actually legal and what falls into a genuine gray area. Understanding cannabis strains and products is valuable, but in Poland, everything starts with a regulated medical system that changed significantly in late 2024.

• Poland has no legal recreational cannabis market; unauthorized possession, sale, and cultivation remain criminal offenses regardless of quantity.
• Medical cannabis has been legal since 2017, obtained only through a physician’s prescription and dispensed at licensed pharmacies, not dispensaries.
• Since November 7, 2024, a cannabis prescription generally requires the prescriber to personally examine the patient, and this applies to prescriptions generally, not only a patient’s first one.
• There’s no single THC percentage that makes every CBD product legal; finished-product legality depends on the product’s category and applicable rules.
• Carrying already-dispensed medical cannabis across a Polish border isn’t automatically illegal, but it requires a specific pharmaceutical-inspector document and is subject to strict conditions.
• Unauthorized possession is generally punishable by up to three years’ imprisonment, rising to one to ten years for a significant quantity; there is no fixed “safe” gram amount.
• Foreign visitors may seek a medical assessment in Poland, but a prescription isn’t guaranteed and depends on an individual physician’s judgment.

Not for recreational use, no. Poland has no legal recreational cannabis market, and possession, sale, or cultivation of cannabis above legal hemp thresholds remains a criminal offense at any quantity.

Medical cannabis has been legal since a 2017 amendment that allows specified cannabis materials to serve as pharmaceutical raw materials for compounded prescription medicines. Patients access it through a licensed physician’s prescription, filled at a regular pharmacy rather than a dispensary.

CBD sits in between. Industrial hemp cultivation is legal under a THC threshold, but that threshold governs the plant, not automatically every finished CBD product. A retail CBD product’s legality depends on its category (food, cosmetic, medicine, or herbal smoking product) and the rules that apply to that category, not on THC percentage alone.

Poland maintains strict cannabis laws that distinguish sharply between medical use, CBD products, and recreational consumption. Anyone researching cannabis education should understand these boundaries before assuming rules from elsewhere apply here.

• Medical cannabis has been legal since 2017, available only through a prescription from a licensed physician. Patients receive specific authorized pharmaceutical raw materials with declared cannabinoid composition, dispensed through licensed pharmacies as prescription medicine.
• CBD products occupy a genuine gray area. Industrial hemp cultivation is legal under a THC threshold, but finished CBD products are regulated according to their category, such as food, cosmetic, medicine, or herbal smoking product, each with its own composition, authorization, and labeling rules. A low THC percentage on its own doesn’t establish that a specific product is legal.
• Recreational cannabis is illegal at any quantity. Possession, sale, and cultivation of non-fiber cannabis carry criminal penalties, including fines and imprisonment.

Polish law doesn’t set a fixed lawful “personal use” quantity. Prosecutors have discretion in charging decisions, and Article 62a allows, but doesn’t require, dismissal where the amount is insignificant, intended for personal use, and punishment would serve no purpose. That’s a discretionary option, not a guaranteed safe threshold, so there’s no quantity that’s definitively protected from prosecution.

The THC threshold is a frequent source of confusion, largely because it means different things depending on context:

• Cultivation threshold. Poland’s industrial-hemp definition uses a 0.3% total-THC standard (the sum of Δ9-THC and THCA, calculated as specified in law). This is a plant and cultivation classification, not a blanket safe harbor for every finished product made from that hemp.
• Finished CBD products. These are governed by category-specific rules. For example, EU food-safety limits for hemp seeds and seed-derived foods are expressed in milligrams per kilogram (3 mg/kg for seeds and most seed products, 7 mg/kg for hemp-seed oil), which is a different kind of limit than a cultivation percentage. A product can fall below a commonly cited THC percentage and still be found noncompliant for other reasons, including unauthorized ingredients.
• Medical cannabis. Prescribed cannabis material isn’t subject to the industrial-hemp THC limit; instead, patients receive specific authorized pharmaceutical raw materials with a declared, regulated cannabinoid profile through the prescription and pharmacy system.

Because finished-product legality depends on category rather than one percentage, Poland’s Chief Sanitary Inspectorate (GIS) periodically removes noncompliant CBD products from stores, including products with low THC content that were found unsuitable for other regulatory reasons. That makes the retail environment worth checking on an ongoing basis rather than relying on a single rule of thumb.

Poland’s medical cannabis prescribing rules changed meaningfully in November 2024, and the change is broader than many patients realize.

Since November 7, 2024, a prescription for medical cannabis (flower, extracts, or resin) generally may be issued only after the prescriber personally examines the patient. This requirement applies to prescriptions generally, not only to a patient’s first prescription.

A narrow exception exists when a doctor providing publicly contracted primary care continues an already-established treatment; this is not a general allowance for private cannabis clinics to issue remote renewals after a single in-person visit. Poland’s Patient Rights Ombudsman has reported enforcement action against providers that didn’t comply with the personal-examination requirement, so patients shouldn’t assume a clinic’s advertised telehealth follow-up is compliant without asking specifically how it fits the exception.

Poland has no official closed list of qualifying diagnoses. A physician determines whether cannabis therapy is medically appropriate for an individual patient after reviewing their diagnosis, prior treatment, risks, contraindications, and the available evidence, rather than automatically qualifying a patient based on a listed condition. Patients are commonly seen for chronic pain, cancer-related symptoms, multiple sclerosis, and epilepsy, among other conditions, but inclusion on any such list by a clinic doesn’t guarantee that treatment will be approved.

The consultation process typically includes a medical history review with supporting documentation, a physical examination, a discussion of treatment goals and prior therapies, education on cannabis products and administration methods, and an e-prescription if the physician determines cannabis therapy is appropriate.

Poland doesn’t have dispensaries. Medical cannabis is dispensed exclusively through pharmacies authorized to handle narcotic medications, and not every pharmacy stocks it.

Private stock-search websites can be a useful starting point for locating pharmacies that may carry a specific product, but their listings aren’t official, government-guaranteed inventory data, so confirm availability directly with the pharmacy by phone before traveling there. Prescription cannabis may be reservable online where a pharmacy offers that option, but lawful dispensing requires collection in person at the physical pharmacy; it can’t be mailed or shipped to a patient as an ordinary online order.

CBD products occupy a genuinely ambiguous legal position that calls for consumer caution. The market exists, and shops operate openly, but regulatory enforcement remains unpredictable, and store presence alone says nothing about whether a specific product complies with the law.

CBD derived from industrial hemp isn’t explicitly banned, but individual products face several regulatory hurdles depending on category:

• Novel-food rules. CBD extracts intended for use as food may fall under EU novel-food rules, which generally require EU authorization before a product can be marketed; the European Food Safety Authority may conduct a scientific safety assessment as part of that authorization process, but authorization itself comes through the EU process rather than from EFSA directly.
• THC content and composition. Products must meet the standards for their category, which can go beyond a simple THC percentage and may include ingredient authorization.
• Marketing restrictions. Shops cannot make medical or therapeutic claims about CBD products.
• Inconsistent enforcement. CBD stores have faced enforcement actions in recent years, sometimes involving products that appeared to meet common THC expectations but were found noncompliant for other reasons.

When shopping for CBD in Warsaw, a few habits reduce your risk, though none of them guarantee legality:

• Review the product category. Understand whether you’re buying something marketed as a food, cosmetic, or other category, since the applicable rules differ.
• Ask about lab testing. A certificate of analysis can offer useful information about cannabinoid content, but it isn’t government approval and doesn’t guarantee the product is legally compliant or that the tested sample matches your specific batch.
• Avoid products making medical claims. Marketing a CBD product as a treatment for a specific condition violates Polish advertising rules.
• Keep your receipt and original packaging. These can help document where and when you bought something, but they don’t establish that a product complies with Polish law if it’s later found noncompliant.
• Check for recalls or sanitary notices. Products presented as medicines in particular should be checked against official medicinal-product and pharmacy registers.

Understanding product labels helps you evaluate what you’re buying, though no single labeling detail guarantees compliance with Polish regulations.

Warsaw has healthcare providers who can assess patients for medical cannabis, though Poland has no special government category of “authorized cannabis clinic.” Patients are assessed by licensed medical professionals working within the general healthcare and controlled-prescription framework, and all currently require an in-person visit under the November 2024 personal-examination rule.

Before booking with any provider, verify the entity and its operating address in Poland’s official Registry of Entities Performing Medical Activity (RPWDL). Being listed in RPWDL confirms that a healthcare entity is registered; it doesn’t guarantee a prescription will be issued, specific pricing, or a particular prescribing quantity. Treatment and dosage are determined by the prescriber after an individual medical assessment, not by a clinic’s advertised practices, so be cautious of any provider that frames a specific prescribed quantity as a selling point.

After receiving your e-prescription (marked RPw for narcotics), the general process is:

1. Locate pharmacy stock. Use a pharmacy stock-search tool or call ahead to pharmacies near you, filtering for your city.
2. Confirm availability by phone. Reserve the product where the pharmacy allows it.
3. Bring identification. To fill an e-prescription with the standard four-digit access code, you’ll typically need the code and your PESEL number (Polish national ID number). A QR code or prescription information printout can also be used. Visitors without a PESEL should ask their prescriber for the appropriate printout or electronic prescription document and confirm identification requirements with the dispensing pharmacy in advance.
4. Verify product details. Check the manufacturer, THC/CBD percentages, batch number, and expiry date at pickup.
5. Pay at pickup. Confirm current pricing and any reimbursement status directly with the pharmacy, since costs and coverage can change and vary by product.

Cannabis flower, oils, and imported products vary in price by manufacturer and pharmacy; check current pricing directly with the pharmacy rather than relying on a fixed figure, since prices shift over time.

Attempting to bypass Poland’s medical system carries serious legal and health consequences.

Polish drug law imposes specific statutory ranges for cannabis offenses:

• Possession. Unauthorized possession is generally punishable by up to three years’ imprisonment. Possession of a significant quantity carries one to ten years. In a lesser case, a court may impose a fine, restriction of liberty, or imprisonment of up to one year. As noted above, prosecutors may discretionarily discontinue certain cases involving an insignificant, personal-use amount, but this isn’t guaranteed, and there’s no fixed gram threshold.
• Cultivation. Unauthorized cultivation of non-fiber cannabis is punishable regardless of plant count, with increased penalties (up to six months to eight years) where the crop could produce a significant quantity. This is separate from Poland’s regulated industrial-hemp cultivation, which operates under its own licensing rules.
• Supply and distribution. Unlawful commercial supply can carry one to ten years’ imprisonment, with higher penalties in specified circumstances; placing drugs into circulation generally carries a fine and six months to eight years, with increased penalties for significant quantities.

Non-citizens may also face immigration consequences depending on their status and the outcome of a case, but deportation isn’t an automatic result of every cannabis offense; it depends on citizenship, residence status, and separate administrative decisions.

There’s no recreational-cannabis purchase age in Poland, because recreational sales are illegal for everyone regardless of age. Medical cannabis for a minor isn’t handled as an “18+” retail rule; it follows ordinary pediatric treatment and consent rules, generally requiring parental or legal-representative consent for a child under 16, and consent from both the patient and legal representative for a patient aged 16 to 17. Age requirements for commercial CBD products can vary depending on the product’s legal category, and any age limit posted by an individual retailer should be treated as store policy rather than assumed to be national law.

Unregulated cannabis presents risks that the medical system avoids, including unknown contaminants like pesticides, heavy metals, or mold, unverifiable potency, possible adulteration with other substances, and no consumer protections or quality guarantees if something goes wrong. Medical cannabis from authorized pharmacies, by contrast, comes with declared cannabinoid composition, sealed packaging with batch numbers, and the legal protections of the regulated system.

A valid prescription changes where you can lawfully obtain cannabis, but it doesn’t create an unrestricted right to consume it anywhere you like.

Poland’s smoke-free law prohibits smoking and e-cigarette use in numerous public venues, including healthcare facilities, schools, workplaces, restaurants, and public transport. Beyond those specific venues, property owners and local rules may impose further restrictions on cannabis use. Because cannabis flower can be difficult to visually distinguish from illicit plant material, it’s worth keeping it in its original pharmacy packaging and avoiding public administration generally, both to comply with venue-specific smoking rules and to avoid unnecessary scrutiny. A prescription is not, on its own, a defense against every possible public-use scenario, but it also doesn’t mean every conceivable outdoor use is automatically a criminal act; the applicable rule depends on the specific venue and conduct.

Polish law prohibits driving after using cannabis, but the standard is more nuanced than a simple detection threshold.

Polish legislation distinguishes driving “after use” of a substance from driving “under the influence” of one, and the statutes don’t set an explicit numerical THC limit the way alcohol has a 0.08-equivalent standard. Polish forensic practice commonly references concentrations around 1 ng/mL and 2.5 ng/mL THC when distinguishing the two states, but these are reference points used in practice, not fixed statutory thresholds, so toxicology, concentration, timing, and expert assessment can all matter to the outcome. THC detection windows also vary significantly with dose, route, frequency, and testing method, and detectable THC can outlast any noticeable impairment.

The practical guidance is straightforward regardless of the technical details: don’t drive after using medical or any other cannabis, a prescription is not a defense to impaired driving, and patients should get individualized advice from their prescriber about timing and driving.

International travel with any cannabis product requires care, and the rules differ meaningfully depending on whether you’re carrying already-dispensed medicine or attempting to fill a prescription abroad.

Polish rules provide a specific procedure for patients to carry their own controlled medicine, including cannabis, across a border for personal treatment. For qualifying travel within the Schengen area, a patient generally needs a document issued or authenticated by the appropriate provincial pharmaceutical inspector. For travel to other countries, the document is issued by Poland’s Chief Pharmaceutical Inspector. These documents are generally limited to the medically necessary quantity and cover no more than 30 days; the original paper document is required, and the destination or transit country may impose its own additional restrictions. Controlled medicine cannot be sent by post or courier under this procedure.

Separately, a Polish RPw-controlled drug e-prescription cannot itself be filled abroad. That’s a different issue from carrying medicine that’s already been lawfully dispensed in Poland; one concerns filling a prescription internationally, the other concerns physically transporting medicine you already have.

If you’re a medical cannabis patient from another country traveling to Poland, understand that your home country’s prescription has no automatic recognition here. Consider whether you can obtain a new assessment and prescription through a Polish provider if you’ll need cannabis during a longer stay, bring your medical records for the Polish physician to review, and plan for the possibility that you may need to manage without cannabis during a short visit. For CBD, avoid assuming that a product’s THC content alone determines how it will be treated at the border; its treatment depends on the product’s classification, composition, and the destination country’s specific rules.

Despite restrictive laws, Poland has an emerging cannabis culture and a growing advocacy movement pushing for reform, including expanded qualifying conditions for medical cannabis, reduced bureaucratic barriers to prescription access, and public education about cannabis. The November 2024 regulatory changes highlighted how directly policy shifts affect patient access and have energized advocacy efforts further.

Industrial hemp cultivation, meanwhile, is legal and growing under its own licensing framework, with applications in textiles, building materials, hemp seed foods and oils, and CBD extraction within regulatory limits. This legitimate industry operates entirely within current law and offers an economic case for continued reform discussions.

Navigating international cannabis regulations requires reliable, current information. Herb is a comprehensive resource for cannabis consumers seeking education beyond basic product listings.

Herb’s strain database offers detailed profiles of thousands of strains, useful context when discussing options with a Polish physician. The platform’s product reviews and educational guides cover consumption methods and product basics, while cannabis news tracks legalization developments across global markets, including changes like Poland’s November 2024 prescribing update.

For anyone researching cannabis access in Poland or any international market, Herb’s educational approach helps you understand not just where products exist, but how to evaluate them and make informed decisions within the applicable legal framework.

Poland offers a real, legal pathway to cannabis, but it runs through the medical system, not a retail market, and the details matter more than they might in a fully legal jurisdiction.

• Seeking medical cannabis as a resident or long-term visitor? Expect an in-person assessment under the November 2024 rule, a physician’s individual judgment on eligibility, and pharmacy pickup rather than dispensary shopping.
• A short-term tourist hoping to access cannabis? It’s possible to seek an assessment, but a prescription isn’t guaranteed, and you’ll need to plan around identification requirements if you don’t have a PESEL number.
• Interested in CBD? Treat any single THC percentage as a starting point, not a guarantee; check the product’s category and look for signs of proper labeling and testing.
• Traveling with cannabis you already have? Understand that crossing into or out of Poland with controlled medicine requires a specific pharmaceutical-inspector document, not just your home prescription.
• Curious about the bigger picture? Poland’s medical cannabis and hemp industries are real and growing, even as recreational cannabis remains fully illegal for now.